You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Generalizing and Standardizing fMRI Tools for Differentiating Mental Illnesses and Predicting Medication-Class Response in Patients

    SBC: ADVANCED BIOMEDICAL INFORMATICS GROUP, L.L.C.            Topic: 102

    Project Summary/AbstractMood disorders, like many psychiatric conditions, have their onset in emerging adulthood and often last a lifetime. Mental illnesses have an excessively large loading of Disability Adjusted Life Years, making early intervention crucial for both individuals and society. Differentiating bipolar disorder (BD) from major depressive disorder (MDD) based on the Diagnostic and Sta ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Abstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermore, infection with PA gener- ally has a poor prognosis, with an estimated 40-69% of PA ventilator-associated pneumonia (VAP) cases re- sulting in mortality, and more than 30% of survivors suffer recur ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)

    SBC: Mulberry Biotherapeutics, Inc.            Topic: NINDS

    Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects about 1 in 25,000 individuals globally. While usually benign, these tumors result in severe morbidity and mortality in affected individuals. Almost all NF2 patients lose their hearing, and many lose the ability to walk and even to see. NF2 patients’ average age at death is 36 years, many of whom die in adolescence or early ad ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Vaccination against Zika virus infection using mosquito NeSt1 protein

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of the main transmitters. The mosquito specie, Aedes aegypti, is the primary mosquito vector of several widely spread arboviruses as zika, dengue or West Nile viruses. Mosquitoes transmit these pathogens by inoculatin ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    The advent of checkpoint inhibitor (CPI) therapy in human cancer has dramatically changed the landscape of treatment strategies in recent years. Previously, cancers with largely ineffective therapeutics and a poor prognosis, such as melanoma, have experienced significant advances of patients able to extend survival and/or progression free disease. Within the tumor microenvironment, a number of imm ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations

    SBC: Photosonox LLC            Topic: NIBIB

    ABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation

    SBC: REBISCAN, Inc.            Topic: N

    Project Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy

    SBC: Endectra LLC            Topic: 102

    PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Treatment of diabetic retinopathy with TrkB agonist antibodies

    SBC: Zebra Biologics, Inc.            Topic: NEI

    Project Summary/AbstractDiabetic retinopathy (DR) is a major co-morbidity for patients with Type 1 and Type 2 diabetes. The incidence and severity of DR increase with duration of diabetes and approximately 30 percent will experience vision-threatening deficits. Work over the past decade has shown that the neural deficits observed in DR occur early in the natural history of the disease and likely p ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss

    SBC: Courage Therapeutics, Inc.            Topic: 300

    Rates of obesity have steadily increased in the United States, with approximately 50 percent of Americans projected to be classified as obese by 2030. Interestingly, obesity even seems to be a risk factor for the severity of illness in response to COVID-19 disease. Although behavioral (dieting and exercise), pharmacological, and surgical approaches exist for weight loss, many individuals who lose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government